Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 5,200 Shares

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,200 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the sale, the chief executive officer now directly owns 667,318 shares of the company’s stock, valued at approximately $32,932,143.30. The trade was a 0.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $53.66 on Thursday. The company’s fifty day moving average is $48.74 and its 200-day moving average is $46.27. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. Analysts expect that Twist Bioscience Co. will post -2.27 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the stock. Van ECK Associates Corp lifted its position in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience in the 3rd quarter valued at $34,000. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. US Bancorp DE lifted its position in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at $95,000.

Analysts Set New Price Targets

A number of analysts recently weighed in on TWST shares. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Scotiabank raised their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.